{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:18:47Z","timestamp":1782137927499,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T00:00:00Z","timestamp":1386633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.anai.2013.12.005","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T22:15:23Z","timestamp":1388787323000},"page":"170-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Real-life experiences with omalizumab for the treatment of chronic urticaria"],"prefix":"10.1016","volume":"112","author":[{"given":"Gordon","family":"Sussman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Caron-Guay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Laflamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2013.12.005_bib1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1398-9995.2009.02179.x","article-title":"EAACI\/GA(2)LEN\/EDF\/WAO guideline: definition, classification and diagnosis of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2013.12.005_bib2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2222.2007.02678.x","article-title":"BSACI guidelines for the management of chronic urticaria and angio-oedema","volume":"37","author":"Powell","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2013.12.005_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1177\/1359105311398682","article-title":"Chronic idiopathic urticaria and anxiety symptoms","volume":"16","author":"Barbosa","year":"2011","journal-title":"J\u00a0Health Psychol"},{"key":"10.1016\/j.anai.2013.12.005_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1468-3083.2007.02324.x","article-title":"The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria","volume":"22","author":"Engin","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2013.12.005_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mjd.2000.104680","article-title":"Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria","volume":"43","author":"Thompson","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2013.12.005_bib6","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1398-9995.2004.00473.x","article-title":"Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients","volume":"59","author":"Toubi","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2013.12.005_bib7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACI\/GA(2)LEN\/EDF\/WAO guideline: management of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2013.12.005_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4168\/aair.2012.4.6.326","article-title":"Treatment of chronic spontaneous urticaria","volume":"4","author":"Kaplan","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"issue":"suppl C","key":"10.1016\/j.anai.2013.12.005_bib9","first-page":"1C","article-title":"Oral corticosteroids in asthma: a review of benefits and risks","volume":"14","author":"Schellenberg","year":"2007","journal-title":"Can Respir J"},{"key":"10.1016\/j.anai.2013.12.005_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1398-9995.2010.02472.x","article-title":"Omalizumab\u2014an effective and safe treatment of therapy-resistant chronic spontaneous urticaria","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2013.12.005_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaci.2010.05.047","article-title":"Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab","volume":"126","author":"Magerl","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2340\/00015555-0884","article-title":"Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab","volume":"90","author":"Vestergaard","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.anai.2013.12.005_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4168\/aair.2012.4.6.357","article-title":"Effects of omalizumab treatment in patients with refractory chronic urticaria","volume":"4","author":"Nam","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.anai.2013.12.005_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1346-8138.2011.01473.x","article-title":"Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey","volume":"39","author":"B\u00fcy\u00fck\u00f6zt\u00fcrk","year":"2012","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.anai.2013.12.005_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000336205","article-title":"Omalizumab for chronic urticaria: a case series and overview of the literature","volume":"4","author":"Ivyanskiy","year":"2012","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.anai.2013.12.005_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1529-8019.2013.01549.x","article-title":"Omalizumab in chronic urticaria: a retrospective series of 15 cases","volume":"26","author":"Armengot-Carbo","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.anai.2013.12.005_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5021\/ad.2013.25.2.242","article-title":"A\u00a0long term case series study of the effect of omalizumab on chronic spontaneous urticaria","volume":"25","author":"Lef\u00e9vre","year":"2013","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.anai.2013.12.005_bib18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/14712598.2013.822484","article-title":"Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice","volume":"13","author":"Labrador-Horrillo","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.anai.2013.12.005_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A\u00a0randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2013.12.005_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2006.04.003","article-title":"Successful treatment of cold-induced urticaria\/anaphylaxis with anti-IgE","volume":"117","author":"Boyce","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000346284","article-title":"Treatment of severe cold contact urticaria with omalizumab: case reports","volume":"4","author":"Brodsk\u00e1","year":"2012","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.anai.2013.12.005_bib26","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2012.10.026","article-title":"Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases","volume":"69","author":"Le Moing","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2013.12.005_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.anai.2012.11.022","article-title":"Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria","volume":"110","author":"Song","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2013.12.005_bib28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"M\u0142ynek","year":"2008","journal-title":"Allergy"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120613009265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120613009265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:09:40Z","timestamp":1761052180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120613009265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1081120613009265"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2013.12.005","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life experiences with omalizumab for the treatment of chronic urticaria","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2013.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}